Latest Drugwonks' Blog
World reknown health care expert Reinhardt complains to the WSJ that he cannot get his extremely large and supple brain around the question about why we stupid Americans don't like socialized medicine:
"Why do I never hear any Republican political candidate, or the editorial page of the Journal for that matter, openly advocate the abolition and privatization of the VA health system? Why are even the staunchest American conservatives, and the veterans themselves, so protective of the VA health system, if socialized medicine is so bad?"
One explanation may be that the VA health system is generally viewed among health-policy experts as the cutting edge in the smart use of electronic information technology and of quality control in health care. The Journal itself featured an article on this point on its front page some time ago. In a peer-reviewed research paper published in the Annals of Internal Medicine (December 21, 2004), researchers of the RAND Corp. reported that the quality of care received by VA patients scored significantly higher overall than did comparable metrics for patients in the rest of the U.S. health system."
Again with the 2004 study (which by the way did not compare metrics with rest of the country, only a couple of other HMOs)
Perhaps Reinhardt hasn't read about the excellent care the VA is delivery to vets with mental illness and PTSD:
"The VA has seen its backlog of disability claims swell to 600,000 as soldiers return from ongoing wars, a logjam blamed for financial dislocation, despair and even suicides of vets. The suit says the claims system is "riddled with inconsistent and irrational procedures" that violate the due process rights of injured vets seeking care and compensation. For example, the VA employs the same officials both to challenge and judge claims.
"According to the suit, the biggest casualties of this bureaucratic morass are the unprecedented number of troops returning with PTSD, a mental disorder especially prevalent in soldiers stationed in Iraq and Afghanistan, where they're faced with multiple tours of duty, invisible battle lines and the "moral ambiguity of killing combatants dressed as civilians." The military says more than a third of the 1.6 million men and women who have served in Iraq or Afghanistan report mental health issues ranging from PTSD to brain injuries, yet only 27 of the nation's 1,400 VA hospitals have programs dedicated to treating PTSD. Worse yet, the complex process of applying for disability payments is especially daunting for these patients, who often experience memory lapses and disorientation."
http://news.yahoo.com/s/time/20070725/us_time/behindtheveteranslegalbattle
"Why do I never hear any Republican political candidate, or the editorial page of the Journal for that matter, openly advocate the abolition and privatization of the VA health system? Why are even the staunchest American conservatives, and the veterans themselves, so protective of the VA health system, if socialized medicine is so bad?"
One explanation may be that the VA health system is generally viewed among health-policy experts as the cutting edge in the smart use of electronic information technology and of quality control in health care. The Journal itself featured an article on this point on its front page some time ago. In a peer-reviewed research paper published in the Annals of Internal Medicine (December 21, 2004), researchers of the RAND Corp. reported that the quality of care received by VA patients scored significantly higher overall than did comparable metrics for patients in the rest of the U.S. health system."
Again with the 2004 study (which by the way did not compare metrics with rest of the country, only a couple of other HMOs)
Perhaps Reinhardt hasn't read about the excellent care the VA is delivery to vets with mental illness and PTSD:
"The VA has seen its backlog of disability claims swell to 600,000 as soldiers return from ongoing wars, a logjam blamed for financial dislocation, despair and even suicides of vets. The suit says the claims system is "riddled with inconsistent and irrational procedures" that violate the due process rights of injured vets seeking care and compensation. For example, the VA employs the same officials both to challenge and judge claims.
"According to the suit, the biggest casualties of this bureaucratic morass are the unprecedented number of troops returning with PTSD, a mental disorder especially prevalent in soldiers stationed in Iraq and Afghanistan, where they're faced with multiple tours of duty, invisible battle lines and the "moral ambiguity of killing combatants dressed as civilians." The military says more than a third of the 1.6 million men and women who have served in Iraq or Afghanistan report mental health issues ranging from PTSD to brain injuries, yet only 27 of the nation's 1,400 VA hospitals have programs dedicated to treating PTSD. Worse yet, the complex process of applying for disability payments is especially daunting for these patients, who often experience memory lapses and disorientation."
http://news.yahoo.com/s/time/20070725/us_time/behindtheveteranslegalbattle
A letter from the current issue of The Economist penned by our friend and colleague Jacob Arfwedson:
Drug tests
SIR – Your leader on the reform of pharmaceutical regulations in America maintains that safety concerns must be addressed, but why assume that the government will do a better job than independent players (“From bench to bedsideâ€, June 30th)? In the United States private agencies ensure quality assessment (including off-label use and risks missed by the government) in a speedier way than the Food and Drug Administration.
As Peter Pitts, a former associate commissioner at the FDA, has shown, there is no direct link between additional clinical trials and safer medicines. The length of the FDA approval process has doubled since the 1960s as have the financial costs since the late 1980s. Moreover, the number of clinical trials doubled between 1977 and 1995 and the number of patients tripled. Yet in the past 40 years the share of medicines withdrawn from the market has remained constant.
Jacob Arfwedson
Centre for the New Europe
Brussels
The rest of the story is that the science of clinical trials needs updating. If we want to truly move into the era of personalized medicine, we need adaptive clinical trials that can look more precisely at sub-populations.
"Traditional" clinical trials that demonstrate a 40% efficacy rate without even attempting to isolate which 40% is expensive in financial terms and only marginally helpful in helping physicians best treat their patients. It also plays into the hands of the Evangelists of Evidence-based Medicine and the Votaries of Me-Tooism. We must think about clinical trials in new ways. It's a crucial aspect of the Critical Path.
Drug tests
SIR – Your leader on the reform of pharmaceutical regulations in America maintains that safety concerns must be addressed, but why assume that the government will do a better job than independent players (“From bench to bedsideâ€, June 30th)? In the United States private agencies ensure quality assessment (including off-label use and risks missed by the government) in a speedier way than the Food and Drug Administration.
As Peter Pitts, a former associate commissioner at the FDA, has shown, there is no direct link between additional clinical trials and safer medicines. The length of the FDA approval process has doubled since the 1960s as have the financial costs since the late 1980s. Moreover, the number of clinical trials doubled between 1977 and 1995 and the number of patients tripled. Yet in the past 40 years the share of medicines withdrawn from the market has remained constant.
Jacob Arfwedson
Centre for the New Europe
Brussels
The rest of the story is that the science of clinical trials needs updating. If we want to truly move into the era of personalized medicine, we need adaptive clinical trials that can look more precisely at sub-populations.
"Traditional" clinical trials that demonstrate a 40% efficacy rate without even attempting to isolate which 40% is expensive in financial terms and only marginally helpful in helping physicians best treat their patients. It also plays into the hands of the Evangelists of Evidence-based Medicine and the Votaries of Me-Tooism. We must think about clinical trials in new ways. It's a crucial aspect of the Critical Path.
From today's Wall Street Journal
Cheese Headcases
When Louis Brandeis praised the 50 states as "laboratories of democracy," he didn't claim that every policy experiment would work. So we hope the eyes of America will turn to Wisconsin, and the effort by Madison Democrats to make that "progressive" state a petri dish for government-run health care.
This exercise is especially instructive, because it reveals where the "single-payer," universal coverage folks end up. Democrats who run the Wisconsin Senate have dropped the Washington pretense of incremental health-care reform and moved directly to passing a plan to insure every resident under the age of 65 in the state. And, wow, is "free" health care expensive. The plan would cost an estimated $15.2 billion, or $3 billion more than the state currently collects in all income, sales and corporate income taxes. It represents an average of $510 a month in higher taxes for every Wisconsin worker.
Employees and businesses would pay for the plan by sharing the cost of a new 14.5% employment tax on wages. Wisconsin businesses would have to compete with out-of-state businesses and foreign rivals while shouldering a 29.8% combined federal-state payroll tax, nearly double the 15.3% payroll tax paid by non-Wisconsin firms for Social Security and Medicare combined.
This employment tax is on top of the $1 billion grab bag of other levies that Democratic Governor Jim Doyle proposed and the tax-happy Senate has also approved, including a $1.25 a pack increase in the cigarette tax, a 10% hike in the corporate tax, and new fees on cars, trucks, hospitals, real estate transactions, oil companies and dry cleaners. In all, the tax burden in the Badger state could rise to 20% of family income, which is slightly more than the average federal tax burden. "At least federal taxes pay for an Army and Navy," quips R.J. Pirlot of the Wisconsin Manufacturers and Commerce business lobby.
As if that's not enough, the health plan includes a tax escalator clause allowing an additional 1.5 percentage point payroll tax to finance higher outlays in the future. This could bring the payroll tax to 16%. One reason to expect costs to soar is that the state may become a mecca for the unemployed, uninsured and sick from all over North America. The legislation doesn't require that you have a job in Wisconsin to qualify, merely that you live in the state for at least 12 months. Cheesehead nation could expect to attract health-care free-riders while losing productive workers who leave for less-taxing climes.
Proponents use the familiar argument for national health care that this will save money (about $1.8 billion a year) through efficiency gains by eliminating the administrative costs of private insurance. And unions and some big businesses with rich union health plans are only too happy to dump these liabilities onto the government.
But those costs won't vanish; they'll merely shift to all taxpayers and businesses. Small employers that can't afford to provide insurance would see their employment costs rise by thousands of dollars per worker, while those that now provide a basic health insurance plan would have to pay $400 to $500 a year more per employee.
The plan is also openly hostile to market incentives that contain costs. Private companies are making modest progress in sweating out health-care inflation by making patients more cost-conscious through increased copayments, health savings accounts, and incentives for wellness. The Wisconsin program moves in the opposite direction: It reduces out-of-pocket copayments, bars money-saving HSA plans, and increases the number of mandated medical services covered under the plan.
So where will savings come from? Where they always do in any government plan: Rationing via price controls and, as costs rise, waiting periods and coverage restrictions. This is Michael Moore's medical dream state.
The last line of defense against this plan are the Republicans who run the Wisconsin House. So far they've been unified and they recently voted the Senate plan down. Democrats are now planning to take their ideas to the voters in legislative races next year, and that's a debate Wisconsinites should look forward to. At least Wisconsin Democrats are admitting how much it will cost Americans to pay for government-run health care. Would that Washington Democrats were as forthright.
Cheese Headcases
When Louis Brandeis praised the 50 states as "laboratories of democracy," he didn't claim that every policy experiment would work. So we hope the eyes of America will turn to Wisconsin, and the effort by Madison Democrats to make that "progressive" state a petri dish for government-run health care.
This exercise is especially instructive, because it reveals where the "single-payer," universal coverage folks end up. Democrats who run the Wisconsin Senate have dropped the Washington pretense of incremental health-care reform and moved directly to passing a plan to insure every resident under the age of 65 in the state. And, wow, is "free" health care expensive. The plan would cost an estimated $15.2 billion, or $3 billion more than the state currently collects in all income, sales and corporate income taxes. It represents an average of $510 a month in higher taxes for every Wisconsin worker.
Employees and businesses would pay for the plan by sharing the cost of a new 14.5% employment tax on wages. Wisconsin businesses would have to compete with out-of-state businesses and foreign rivals while shouldering a 29.8% combined federal-state payroll tax, nearly double the 15.3% payroll tax paid by non-Wisconsin firms for Social Security and Medicare combined.
This employment tax is on top of the $1 billion grab bag of other levies that Democratic Governor Jim Doyle proposed and the tax-happy Senate has also approved, including a $1.25 a pack increase in the cigarette tax, a 10% hike in the corporate tax, and new fees on cars, trucks, hospitals, real estate transactions, oil companies and dry cleaners. In all, the tax burden in the Badger state could rise to 20% of family income, which is slightly more than the average federal tax burden. "At least federal taxes pay for an Army and Navy," quips R.J. Pirlot of the Wisconsin Manufacturers and Commerce business lobby.
As if that's not enough, the health plan includes a tax escalator clause allowing an additional 1.5 percentage point payroll tax to finance higher outlays in the future. This could bring the payroll tax to 16%. One reason to expect costs to soar is that the state may become a mecca for the unemployed, uninsured and sick from all over North America. The legislation doesn't require that you have a job in Wisconsin to qualify, merely that you live in the state for at least 12 months. Cheesehead nation could expect to attract health-care free-riders while losing productive workers who leave for less-taxing climes.
Proponents use the familiar argument for national health care that this will save money (about $1.8 billion a year) through efficiency gains by eliminating the administrative costs of private insurance. And unions and some big businesses with rich union health plans are only too happy to dump these liabilities onto the government.
But those costs won't vanish; they'll merely shift to all taxpayers and businesses. Small employers that can't afford to provide insurance would see their employment costs rise by thousands of dollars per worker, while those that now provide a basic health insurance plan would have to pay $400 to $500 a year more per employee.
The plan is also openly hostile to market incentives that contain costs. Private companies are making modest progress in sweating out health-care inflation by making patients more cost-conscious through increased copayments, health savings accounts, and incentives for wellness. The Wisconsin program moves in the opposite direction: It reduces out-of-pocket copayments, bars money-saving HSA plans, and increases the number of mandated medical services covered under the plan.
So where will savings come from? Where they always do in any government plan: Rationing via price controls and, as costs rise, waiting periods and coverage restrictions. This is Michael Moore's medical dream state.
The last line of defense against this plan are the Republicans who run the Wisconsin House. So far they've been unified and they recently voted the Senate plan down. Democrats are now planning to take their ideas to the voters in legislative races next year, and that's a debate Wisconsinites should look forward to. At least Wisconsin Democrats are admitting how much it will cost Americans to pay for government-run health care. Would that Washington Democrats were as forthright.
Nearly 15 years ago, when then-First Lady Hillary Clinton proposed to restructure American health care in the image of the European and Canadian systems, most health insurance providers blasted her plan.
What a difference a few years make. Just last month, Senator Clinton and the very same insurers -- in their current incarnation as a trade group called America's Health Insurance Plans -- stood shoulder-to-shoulder in support of such a scheme. Their plan would give the federal government the power to determine what new medicines and services to cover based on budgetary considerations.
So what's changed? Not Senator Clinton -- she has always regarded government as the best arbiter of health care value.
It's the health insurers who have flipped, thinking the scheme will help them save a few bucks.
The model for this marriage of old foes is Britain's National Institute for Clinical Excellence (NICE), which employs comparative effectiveness studies in evaluating whether to pay for new and often expensive medicines.
More often than not, NICE recommends against using the new treatment because it's not "cost-effective" when compared to existing treatments.
That's why many Britons refer to NICE as "NASTY" -- "Not available, so treat yourself."
As health care costs have risen, many policymakers and insurance industry elites have declared that innovative and life-changing new treatments are not worth the price. What a disaster it would be for medical innovation if a narrow-minded focus on cost took precedence over new treatments, new drugs, and personalized health care decision-making.
Here's the rest of the story as reported in the Wisconsin State Journal:
http://www.madison.com/wsj/home/column/other/index/php?ntid=202448&ntpid=4
On Wisconsin!
What a difference a few years make. Just last month, Senator Clinton and the very same insurers -- in their current incarnation as a trade group called America's Health Insurance Plans -- stood shoulder-to-shoulder in support of such a scheme. Their plan would give the federal government the power to determine what new medicines and services to cover based on budgetary considerations.
So what's changed? Not Senator Clinton -- she has always regarded government as the best arbiter of health care value.
It's the health insurers who have flipped, thinking the scheme will help them save a few bucks.
The model for this marriage of old foes is Britain's National Institute for Clinical Excellence (NICE), which employs comparative effectiveness studies in evaluating whether to pay for new and often expensive medicines.
More often than not, NICE recommends against using the new treatment because it's not "cost-effective" when compared to existing treatments.
That's why many Britons refer to NICE as "NASTY" -- "Not available, so treat yourself."
As health care costs have risen, many policymakers and insurance industry elites have declared that innovative and life-changing new treatments are not worth the price. What a disaster it would be for medical innovation if a narrow-minded focus on cost took precedence over new treatments, new drugs, and personalized health care decision-making.
Here's the rest of the story as reported in the Wisconsin State Journal:
http://www.madison.com/wsj/home/column/other/index/php?ntid=202448&ntpid=4
On Wisconsin!
What's on the minds of Turkish journalists covering health care ... counterfeit medicines.
Here's an article that ran in one of that country's largest national daily newspapers, "Dunya"
http://cmpi.org/images/headlines/dunya_1407_pp.jpg
And, for those of you non-Turkish speakers, here's the translation ...
Counterfeit drugs are a major problem for our country, too
One of the most important factors that play a role in the prevention and treatment of diseases is undoubtedly drugs. When successfully treated, conditions such as hypertension are prevented from leading to strokes or heart attacks and drugs that provide effective treatment for diseases such as cancer, AIDS and Alzheimer’s also play a vital role.
Seen from this perspective, an expeditious introduction of new and effective (innovative) drugs for patients’ use does not increase healthcare costs; on the contrary, it is one of the most important factors that reduce healthcare costs. Countries that do not single out cost as a top criterion and take into consideration the overall benefit that a certain drug provides have a healthier social structure and are also able to control their total healthcare costs more easily. There is a large number of scientific studies that confirm the validity of this approach.
In our country, the cost of treatment is almost always viewed as identical to the cost of the associated drug. The rationale behind this approach is that “drugs†represent the measurable and avoidable aspect of basic healthcare costs. The government presents an approach whereby it directly prevents innovative drugs, which are relatively expensive due to their R&D costs, from being put at the service of society.
As a consequence, the number of saved lives decreases and, due to other healthcare expenditures, total healthcare costs inevitably increase. This governmental approach targets all pharmaceutical companies, local and foreign.
Delays in registration play a role in the rise of counterfeit drugs
The fact that innovative drugs have a higher price tag and are not reimbursed by the government has another important repercussion – the rise in counterfeit drugs. Two recent examples in our country presented a clear proof of this phenomenon. Counterfeit versions of two drugs, one for erectile dysfunction, the other for cancer treatment, were clandestinely released into the market. In his recent visit to Turkey, the former Associate Commissioner for External Relations at the American Food and Drug Administration (FDA), Mr. Pitts related his experience on counterfeit drugs. At a press meeting he organized at the Head Office of the Association of Research-Based Pharmaceutical Companies (AIFD), Pitts stated that the expeditious presentation of newly developed and safe drugs at the service of patients has become a priority throughout the whole world and emphasized that, thanks to this approach, patients have increased chances of surviving diseases such as cancer, MS and Alzheimer’s. Pitts pointed out that Turkey’s predominantly young population is a major advantage and that an expeditious introduction of effective drugs at the service of patients without much delay would allow chronic diseases to be treated in a timely manner which would potentially reduce heavier treatment costs down the line.
Buy your drugs only at pharmacies
However, the single most important issue that Pitts emphasized involved counterfeit drugs from China, Russia and South American countries and the damage they cause on human health. Pitts said that as counterfeit drugs provide significant profits, it has become increasingly difficult to fight them and that, in order to avoid counterfeit drugs, individuals must first be wary of environments where counterfeit drugs may be sold and they should not be swayed by the relatively inexpensive prices of these drugs.
Accordingly, it is very important to closely monitor each stage of the distribution channels, to place a barcode and identification on each drug package and to systematically implement as well as increase penal sanctions. Therefore, our most vital suggestions to protect ourselves from counterfeit drugs is to “purchase drugs from pharmacies and refuse to purchase drugs without barcodesâ€.
Nearly all cases of counterfeit drugs in our country up until now have resulted from drugs outside the official distribution channels. The proper approach that will fundamentally resolve the problem is to shorten the registration process for innovative drugs and expeditiously present them at the service of our citizens.
Ankara's Away!
Here's an article that ran in one of that country's largest national daily newspapers, "Dunya"
http://cmpi.org/images/headlines/dunya_1407_pp.jpg
And, for those of you non-Turkish speakers, here's the translation ...
Counterfeit drugs are a major problem for our country, too
One of the most important factors that play a role in the prevention and treatment of diseases is undoubtedly drugs. When successfully treated, conditions such as hypertension are prevented from leading to strokes or heart attacks and drugs that provide effective treatment for diseases such as cancer, AIDS and Alzheimer’s also play a vital role.
Seen from this perspective, an expeditious introduction of new and effective (innovative) drugs for patients’ use does not increase healthcare costs; on the contrary, it is one of the most important factors that reduce healthcare costs. Countries that do not single out cost as a top criterion and take into consideration the overall benefit that a certain drug provides have a healthier social structure and are also able to control their total healthcare costs more easily. There is a large number of scientific studies that confirm the validity of this approach.
In our country, the cost of treatment is almost always viewed as identical to the cost of the associated drug. The rationale behind this approach is that “drugs†represent the measurable and avoidable aspect of basic healthcare costs. The government presents an approach whereby it directly prevents innovative drugs, which are relatively expensive due to their R&D costs, from being put at the service of society.
As a consequence, the number of saved lives decreases and, due to other healthcare expenditures, total healthcare costs inevitably increase. This governmental approach targets all pharmaceutical companies, local and foreign.
Delays in registration play a role in the rise of counterfeit drugs
The fact that innovative drugs have a higher price tag and are not reimbursed by the government has another important repercussion – the rise in counterfeit drugs. Two recent examples in our country presented a clear proof of this phenomenon. Counterfeit versions of two drugs, one for erectile dysfunction, the other for cancer treatment, were clandestinely released into the market. In his recent visit to Turkey, the former Associate Commissioner for External Relations at the American Food and Drug Administration (FDA), Mr. Pitts related his experience on counterfeit drugs. At a press meeting he organized at the Head Office of the Association of Research-Based Pharmaceutical Companies (AIFD), Pitts stated that the expeditious presentation of newly developed and safe drugs at the service of patients has become a priority throughout the whole world and emphasized that, thanks to this approach, patients have increased chances of surviving diseases such as cancer, MS and Alzheimer’s. Pitts pointed out that Turkey’s predominantly young population is a major advantage and that an expeditious introduction of effective drugs at the service of patients without much delay would allow chronic diseases to be treated in a timely manner which would potentially reduce heavier treatment costs down the line.
Buy your drugs only at pharmacies
However, the single most important issue that Pitts emphasized involved counterfeit drugs from China, Russia and South American countries and the damage they cause on human health. Pitts said that as counterfeit drugs provide significant profits, it has become increasingly difficult to fight them and that, in order to avoid counterfeit drugs, individuals must first be wary of environments where counterfeit drugs may be sold and they should not be swayed by the relatively inexpensive prices of these drugs.
Accordingly, it is very important to closely monitor each stage of the distribution channels, to place a barcode and identification on each drug package and to systematically implement as well as increase penal sanctions. Therefore, our most vital suggestions to protect ourselves from counterfeit drugs is to “purchase drugs from pharmacies and refuse to purchase drugs without barcodesâ€.
Nearly all cases of counterfeit drugs in our country up until now have resulted from drugs outside the official distribution channels. The proper approach that will fundamentally resolve the problem is to shorten the registration process for innovative drugs and expeditiously present them at the service of our citizens.
Ankara's Away!
It is obvious Nissen tailors his remarks to the audience....so here he is talking trash about Andy von Eschenbach and Scott Gottlieb to an NPR crowd a while back...
Dr Steven Nissen, chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, was recently a member of a panel debating the topic of: "Government Science Panels: Fair and Balanced?" which was moderated by National Public Radio's Snigdha Prakash, and sponsored the Center for Science in the Public Interest on Aug. 2 2006.
Dr Nissen spoke about the conflict-of-interest problems "evident at the highest levels of the FDA," the article says.
"For years," Dr Nissen said in describing FDA leadership, "we had an interim FDA Commissioner, Lester Crawford, who shortly after confirmation, abruptly resigns, apparently because he and his wife owned stock in regulated companies."
"Then the administration appointed Andrew Von Eschenbach as interim commissioner, creating another conflict," he noted.
"In his role as director of the National Cancer Institute," Dr Nissen said, "Von Eschenbach must seek FDA approval for human testing or approval of new cancer drugs, an obvious conflict."
But even worse, he said, "the administration appointed Scott Gottlieb as deputy commissioner."
"He came to this job with no regulatory experience, directly from Wall Street, where he served as a biotech analyst and stock promoter
"Between them, Drs. Von Eschenbach and Gottlieb have whined incessantly about the need to speed drug development."
"So while the American people worry about the safety of drug the top FDA leadership tells us we need faster drug approval."
Funny, I thought people cared about both. And for such a smart guy who wants to be FDA commish, the inability to conceive of faster drug approval and safer medicines being one in the same reflects scientific stupidity or political cupidity, or both. And for someone whose own studies have demonstrated excess mortality in the wake of promoting the stocks of companies he conducts research for, I would not be talking about putting profits before safety if I were him.
Dr Steven Nissen, chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, was recently a member of a panel debating the topic of: "Government Science Panels: Fair and Balanced?" which was moderated by National Public Radio's Snigdha Prakash, and sponsored the Center for Science in the Public Interest on Aug. 2 2006.
Dr Nissen spoke about the conflict-of-interest problems "evident at the highest levels of the FDA," the article says.
"For years," Dr Nissen said in describing FDA leadership, "we had an interim FDA Commissioner, Lester Crawford, who shortly after confirmation, abruptly resigns, apparently because he and his wife owned stock in regulated companies."
"Then the administration appointed Andrew Von Eschenbach as interim commissioner, creating another conflict," he noted.
"In his role as director of the National Cancer Institute," Dr Nissen said, "Von Eschenbach must seek FDA approval for human testing or approval of new cancer drugs, an obvious conflict."
But even worse, he said, "the administration appointed Scott Gottlieb as deputy commissioner."
"He came to this job with no regulatory experience, directly from Wall Street, where he served as a biotech analyst and stock promoter
"Between them, Drs. Von Eschenbach and Gottlieb have whined incessantly about the need to speed drug development."
"So while the American people worry about the safety of drug the top FDA leadership tells us we need faster drug approval."
Funny, I thought people cared about both. And for such a smart guy who wants to be FDA commish, the inability to conceive of faster drug approval and safer medicines being one in the same reflects scientific stupidity or political cupidity, or both. And for someone whose own studies have demonstrated excess mortality in the wake of promoting the stocks of companies he conducts research for, I would not be talking about putting profits before safety if I were him.
I have decided to pull together the best of the blog commentary on Nissen's Avandia study:
From the Angry Pharmacist
http://www.theangrypharmacist.com/archives/2007/05/avandia_oh_why.html
From Respectful Insolence..
http://scienceblogs.com/insolence/2007/05/well_well_well_what_have_we_here_about_t_1.php
Kevin MD (who cites Medpage who cites but does not attribute my comparison of the WHI to Avandia risk)
http://www.kevinmd.com/blog/2007/05/avandia-and-heart-attacks.html
Dr. Kevin links to Nissen -- one day after making his Avandia > 9-11 tragedy with this ask and answer with Newsweek:
"Is there a case for prescribing Avandia? Are there some patients for whom the benefits outweigh the risks?
Again, I don’t think I want to go there. It’s important for me as a physician-scientist to put the data out there in a very neutral fashion, and not cast judgment about what people ought to do. We’re going to let everybody read our paper and make up their own minds. Obviously the FDA read our paper because they just issued a safety alert."
What a creep.
http://www.msnbc.msn.com/id/18789572/site/newsweek/
From the Angry Pharmacist
http://www.theangrypharmacist.com/archives/2007/05/avandia_oh_why.html
From Respectful Insolence..
http://scienceblogs.com/insolence/2007/05/well_well_well_what_have_we_here_about_t_1.php
Kevin MD (who cites Medpage who cites but does not attribute my comparison of the WHI to Avandia risk)
http://www.kevinmd.com/blog/2007/05/avandia-and-heart-attacks.html
Dr. Kevin links to Nissen -- one day after making his Avandia > 9-11 tragedy with this ask and answer with Newsweek:
"Is there a case for prescribing Avandia? Are there some patients for whom the benefits outweigh the risks?
Again, I don’t think I want to go there. It’s important for me as a physician-scientist to put the data out there in a very neutral fashion, and not cast judgment about what people ought to do. We’re going to let everybody read our paper and make up their own minds. Obviously the FDA read our paper because they just issued a safety alert."
What a creep.
http://www.msnbc.msn.com/id/18789572/site/newsweek/
Yes, Steve Nissen has sleepless nights about drug safety, particularly about the misuse of surrogate endpoints to approve drugs (which is why he has developed IVUS to develop a surrogate endpoint for drug approval).
And he compares Avandia's risk of death to that of 9-11 (though even his own meta-analysis did not estimate increased number of deaths only risk of having a heart attack sooner and not death).
He tells Diedtra Henderson of the Boston Globe he doesn't want to be FDA commissioner but tells the NYT he won't rule it out.
He uses the "I give all my money to charity" line but there is nothing about the fact the charities are his own research organizations and the Steven E Nissen Healthy Heart fund that doled out gym memberships and travel money to people at the ACC.
He is described as an "informal advisor to Congress" on drug safety. How about someone who coordinated with Congress to preempt the FDA's own analysis of Avandia in order stoke support for alternative FDA reform proposals. Who was working with Congressman Waxman and the NEJM to release his paper, supposedly told a Glaxo rep he was going to "destroy Avandia" but had the chutzpah to claim to the media he offered Glaxo the chance to co-author a paper.
Nissen's behavior with respect to Avandia and the increasing criticism that has been leveled at his "study" (if all the short term data showed a 40 percent increased risk, why is there no hint of it in long term studies like RECORD) were all neglected in the NYT study.
I predict that when all is said and done Nissen will be revealed as the Michael Nifong of medical research.
http://www.nytimes.com/2007/07/22/business/22nissen.html
And he compares Avandia's risk of death to that of 9-11 (though even his own meta-analysis did not estimate increased number of deaths only risk of having a heart attack sooner and not death).
He tells Diedtra Henderson of the Boston Globe he doesn't want to be FDA commissioner but tells the NYT he won't rule it out.
He uses the "I give all my money to charity" line but there is nothing about the fact the charities are his own research organizations and the Steven E Nissen Healthy Heart fund that doled out gym memberships and travel money to people at the ACC.
He is described as an "informal advisor to Congress" on drug safety. How about someone who coordinated with Congress to preempt the FDA's own analysis of Avandia in order stoke support for alternative FDA reform proposals. Who was working with Congressman Waxman and the NEJM to release his paper, supposedly told a Glaxo rep he was going to "destroy Avandia" but had the chutzpah to claim to the media he offered Glaxo the chance to co-author a paper.
Nissen's behavior with respect to Avandia and the increasing criticism that has been leveled at his "study" (if all the short term data showed a 40 percent increased risk, why is there no hint of it in long term studies like RECORD) were all neglected in the NYT study.
I predict that when all is said and done Nissen will be revealed as the Michael Nifong of medical research.
http://www.nytimes.com/2007/07/22/business/22nissen.html
Last week I had the opportunity to speak to a roundtable of Turkish journalists on how the second largest nation in Europe can help to reinvent and reinvigorate its health care system.
We talked about why getting new drugs to market in a timely manner is in the best interest of the public health. We talked about how government-run health care systemts often make the mistake of focusing on cost-based rather than patient-centric care. We talked about the dangers of counterfeiting. We talked about the need to develop better "evidence" for the era of personalized medicine. We talked about the urgent need to design a health care system that stresses prevention and chronic care.
In short, it sounded very much like the health care debate in Europe and the United States.
Except there's one enormous difference -- Turkey, demographically speaking, is a young nation. And that's a terrific opportunity. Rather than focusing on the health care needs of a fast-aging population (as is the case in the US and the EU), Turkey has the chance to "start young and stay healthy" -- avoiding many of the "chronic" problems we now face (diabetes, hypertension, high cholesterol, obesity, etc.)
Turkey has the chance to avoid these health care anchors and show us all how to do it right.
We talked about why getting new drugs to market in a timely manner is in the best interest of the public health. We talked about how government-run health care systemts often make the mistake of focusing on cost-based rather than patient-centric care. We talked about the dangers of counterfeiting. We talked about the need to develop better "evidence" for the era of personalized medicine. We talked about the urgent need to design a health care system that stresses prevention and chronic care.
In short, it sounded very much like the health care debate in Europe and the United States.
Except there's one enormous difference -- Turkey, demographically speaking, is a young nation. And that's a terrific opportunity. Rather than focusing on the health care needs of a fast-aging population (as is the case in the US and the EU), Turkey has the chance to "start young and stay healthy" -- avoiding many of the "chronic" problems we now face (diabetes, hypertension, high cholesterol, obesity, etc.)
Turkey has the chance to avoid these health care anchors and show us all how to do it right.
Take a look at who is board leader in conflict cash for the upcoming Avandia Adcomm.
Steve Nissen is pocketing nearly $1 million in study money from companies that are directly competing AGAINST Avandia. The rest of the folks have stock and speaking fees less than $10K per. In fact, St. Steven the Pure has racked up more conflict cash than the rest of the exemption seeking members combined..
And the media? Why, nary a word on the conflict back when or now even as Steve spins them feverishly in the lead up to Adcomm.
http://www.fda.gov/ohrms/dockets/ac/07/waivers/2007-4308w1-00-index.htm
Steve Nissen is pocketing nearly $1 million in study money from companies that are directly competing AGAINST Avandia. The rest of the folks have stock and speaking fees less than $10K per. In fact, St. Steven the Pure has racked up more conflict cash than the rest of the exemption seeking members combined..
And the media? Why, nary a word on the conflict back when or now even as Steve spins them feverishly in the lead up to Adcomm.
http://www.fda.gov/ohrms/dockets/ac/07/waivers/2007-4308w1-00-index.htm
Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.
